Biotech & Life Sciences

Currently Invested Projects


The ExciteBCI technology is a novel approach to rehabilitation. ExciteBCI increases the excitability of the brain, promoting neural plasticity following damage, such as after stroke. Using Brain Computer Interface (BCI) to drive a neuromodulatory intervention the ExciteBCI helps to rewire the brain in readiness for relearning movement. Preliminary studies have shown that it is both effective and fast. Evidence indicates that significant improvements in functional outcomes in people with chronic stroke are seen after just 3 sessions. Typically, such functional improvements take months to achieve.

Contact: Enrico Tronchin,

Wearable Walking Prescription and Monitoring Device

Development of a wearable walking prescription and monitoring device.

Contact: Tracey Smith,

Pelvic Floor Pressure sensor
Development of a new vaginal pressure sensor which will allow concurrent measurement of abdominal and pelvic floor muscle activity. It will also enable measurement of where the pressure changes occur along the length of the vagina which will add to our understanding of how this change might influence the development of pelvic floor muscle disorders such as incontinence and pelvic organ prolapse.        

Contact: Kent Lee,

Formus - Designing an acetabular reconstruction implant
Formus delivers intelligent custom design workflows presented as a webservice that allows engineers and surgeons to collaboratively view and modify custom implant designs in real time, reducing design time from 35 to 5 hours. The result is a more robust implant for the patient, higher satisfaction rates for the surgeon, and cost savings and scalability for the custom implant provider.

Contact: Stephen Flint,

Keratoconus is an eye disease in which thinning and weakening of the cornea results in loss of vision. It is a non-inflammatory eye condition in which the normally round dome-shaped cornea progressively thins causing a cone-like bulge to develop. Keratoconus occurs in 1 in 2000 people worldwide and results in a large number of corneal transplants. Researchers from the University of Auckland Department of Ophthalmology have developed a topical eye formula to treat and reverse the symptoms of Keratoconus without the need for invasive ocular surgery. Preclinical ex-vivo large animal studies have shown efficacy of the formulation in reprogramming stromal keratoncyes to deposit new non-scarring collagen. A PCT has been filed and peer reviewed journal articles are available for review.      

Contact: Stephen Flint,

Perforin Small Molecule Inhibitors

First in class small molecule inhibitors of perforin for use in transplant rejection in a number of different indications. The initial focus indication is on protecting bone marrow stem cells against immune destruction following transplant. The protein Perforin is a potent toxin generated by killer cells of the immune system. Perforin’s molecular structure and confirmed that it destroys cells, by punching large holes in the cell surface. This current work to generate a clinical candidate has been funded by the Wellcome Trust grant of NZ$8.8M.

Contact: Adam Podmore, +64 21 481 124, +64 9 923 8458